

inflammation of the optic nerve or retina of said human, or for modulating the immune response affecting the optic nerve or retina of said human, comprising the step of:


AL
a) administering a therapeutically effective dosage level to said human of said TNF antagonist selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), [other agents containing soluble TNF receptors,] CDP571 (a humanized monoclonal anti-TNF-alpha antibody), [other monoclonal anti-TNF-alpha antibodies, TNF - alpha converting enzyme inhibitors] and D2E7 (a human anti-TNF mAb) for reducing the inflammation of the optic nerve or retina of said human, or for modulating the immune response affecting the optic nerve or retina of said human.

REMARKS

As a result of this Amendment, Claims 30 to 49, and 98 and 99 remain in this divisional application.

Respectfully submitted,

EZRA SUTTON, P.A.


EZRA SUTTON
Reg. No. 25,770

Plaza 9, 900 Route 9
Woodbridge, New Jersey 07095
(732) 634-3520

ES/et
Enclosures